Index · Artikel · Novartis muscle wasting drug gets 'breakthrough' status

Novartis muscle wasting drug gets 'breakthrough' status

2013-08-20 4

résuméZURICH Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM). The U.S. Food and Drug Administ

ZURICH Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM).

The U.S. Food and Drug Administration (FDA) created the "breakthrough therapy" designation earlier this year for medicines deemed likely to demonstrate "substantial improvement" over existing drugs.

sIBM is a rare yet potentially life-threatening muscle-wasting condition. Patients suffering from the disease can gradually lose the ability to walk. There are currently no approved treatments, according to Novartis.

Bimagrumab was developed by Novartis in collaboration with Morphosys. The drug works by stimulating muscle growth by blocking from inhibitory molecules.

(This corrects day of the week to Tuesday from Thursday)

(Reporting by Caroline Copley)

NOVARTIS

Novartis muscle wasting drug gets 'breakthrough' status

ZURICH Novartis said on Tuesday U.S. regulators have granted breakthrough therapy status for its investigational compound bimagrumab for the potential treatment of patients with sporadic inclusion body myositis (sIBM). The U.S. Food and Drug Administ

2013-08-20 NOVARTIS
Novartis aims to show strength with muscle wasting drug

BASEL Fifteen years ago Ian Parkhill was diagnosed with a rare muscle-wasting disease that gradually robbed him of the strength in his thighs. Now, he struggles to walk. The waning muscle in his arms will soon hinder his ability to pull himself out o

2013-12-06 DRUG NOVARTIS MUSCLEWASTING
FDA delays decision on Sarepta's muscle-wasting disorder drug

n">The U.S. Food and Drug Administration deferred a highly anticipated decision on whether to approve Sarepta Therapeutics Inc's muscle-wasting disorder drug, a month after an advisory panel determined that the treatment was not effective. Sarepta

2016-05-25 FDA SAREPTA
Novartis bone marrow drug improves progression-free survival

ZURICH An experimental drug from Novartis significantly improved the length of time that patients lived with a type of bone marrow cancer without the disease worsening, according to a late-stage study presented on Monday. The Phase III trial in patie

2014-06-02 DRUG NOVARTIS
Sarepta says FDA asks for more data for its muscle-wasting treatment

n">Sarepta Therapeutics Inc said the U.S. Food and Drug Administration has requested for additional data for its muscle-wasting treatment as the agency decides whether to approve the drug or not. Shares of the company rose 24 percent to $19.90 in

2016-06-06 FDA SAREPTA
FDA seeks more data on Sarepta muscle disorder drug, shares slump

n">Sarepta Therapeutics Inc suffered yet another setback after U.S. regulators asked for more data on its experimental muscle disorder drug, a move that further delays the marketing application for the treatment. Nearly a third of Sarepta's market

2014-10-27 FDA SAREPTA
Novartis blood cancer drug wins U.S. OK after setback

n">The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended agai

2015-02-23 FDA NOVARTIS
Novartis heart drug gets FDA's 'breakthrough' status

ZURICH Swiss pharmaceuticals company Novartis said on Friday U.S. regulators have given breakthrough therapy status to an investigational treatment for patients with acute heart failure, potentially fast tracking its development and approval. The U.S

2013-06-21 NOVARTIS
Novartis' meningitis B vaccine wins breakthrough therapy status in U.S.

ZURICH Novartis said U.S. health regulators have granted the Swiss drugmaker's meningitis B vaccine Bexsero breakthrough therapy status. The Basel-based company in a statement on Monday said it plans to file for U.S. approval of Bexsero as early as t

2014-04-07 USA NOVARTIS BEXSERO
AstraZeneca wins FDA breakthrough status for key cancer drug

LONDON The U.S. Food and Drug Administration has granted breakthrough therapy designation to AstraZeneca's biggest new drug hope ‍durvalumab as a treatment in bladder cancer, the drugmaker said on Wednesday. The experimental medicine is a so-called P

2016-02-17 CANCER Astrazeneca
Pfizer cancer drug wins special status; shares jump

n">U.S. regulators have granted a "breakthrough therapy" designation to an experimental Pfizer Inc treatment for breast cancer, lifting the company's shares and putting a spotlight on its growing cancer-drug portfolio. Analysts from JPMo

2013-04-10 PFIZER PALBOCICLIB
Ersatzhaut für Verbrennungsopfer Orphan-Drug-und biologischen Status von der FDA erteilt

Eine Gewebeersatztherapie eine Ersatzhaut zu schaffen katastrophalen Brandopfern eigenen Hautzellen 'wurde ein kombiniertes Orphan-Drug-und biologischen Produkt Status von der US Food and Drug Administration unter Verwendung der zur Behandlung von Pa

2012-06-13 New Jersey Philadelphia
FDA staff question Novartis cystic fibrosis drug

WASHINGTON U.S. drug reviewers questioned whether Novartis AG's experimental inhaled antibiotic powder truly helped cystic fibrosis patients breathe better, according to documents posted by the Food and Drug Administration on its website Friday. The

2012-08-31 FDA NOVARTIS
FDA panel backs Novartis cystic fibrosis drug

WASHINGTON Drug advisers on Wednesday backed a new form of Novartis AG's inhaled antibiotic that treats a lung infection linked to cystic fibrosis. A panel of outside advisers to the Food and Drug Administration voted 13 to 1 that Novartis had demons

2012-09-05 FDA NOVARTIS CYSTIC
US FDA probes brain infection in patient on Novartis's MS drug

n">The U.S. Food and Drug Administration said it was investigating a case of a rare and serious brain infection that developed in a patient in Europe, who was being treated with Novartis's multiple sclerosis drug, Gilenya. The FDA said this was th

2013-08-29 FDA NOVARTIS WARNING
FDA staff review recommends against Novartis heart failure drug

WASHINGTON A drug to treat acute heart failure made by Novartis AG should not be approved because there is insufficient evidence to show it improves symptoms, according to an initial review by the U.S. Food and Drug Administration. The review, posted

2014-03-25 FDA NOVARTIS DOCUMENTS
Novartis closes heart drug study early after strong results

ZURICH Novartis has ended a late-stage clinical trial of a chronic heart failure drug early, following strong interim results, giving the Swiss drugmaker a boost after recent setbacks to another heart failure medicine. The Basel-based firm said on Mo

2014-03-31 STUDY NOVARTIS HEARTDRUG
U.S. regulator rejects Novartis heart failure drug

ZURICH U.S. health regulators turned down an application to approve Novartis' experimental heart failure drug due to insufficient evidence that it improves symptoms, the Swiss drugmaker said on Friday. Novartis said in a statement the Food and Drug A

2014-05-16 NOVARTIS SERELAXIN
EU agency recommends against Novartis heart failure drug

ZURICH EU health regulators have recommended against approving Novartis's experimental heart failure drug for the second time this year due to insufficient evidence it improves symptoms, the Swiss drugmaker said in a statement on Friday. The ruling b

2014-05-23 NOVARTIS SERELAXIN
FDA sets approval path for Prosensa muscle disorder drug

n">Prosensa Holding NV said the U.S. Food and Drug Administration had outlined an accelerated regulatory approval path for its most advanced drug, aimed at treating a muscle disorder. The Netherlands-based company said on Tuesday it planned to con

2014-06-03 FDA PROSENSA

TOP

Day/
Week/
Original/
Recommand

Updated

Lexapro: Schläfrigkeit, Depressionen und andere?
Da Yahoo Answers fehlgeschlagen Ich begann vor kurzem Lexapro für meine Depression und Angst nehmen. Ich nehme nur eine Pille pro Morgen von etwa 10 mg. Ich kann das nicht mehr. Ich beginne in zufälligen Zeitabständen zu schlafen. Zum Beispiel: Ich k
Climate change may extend allergy season: study
WASHINGTON Sneezing, congestion, and runny noses from hay fever may be lasting longer because climate change may be extending pollen seasons, doctors in Italy said on Monday. Pollen seasons as well as the amount of pollen in the air progressively inc
Ich habe nicht eine bm für 7 Tage hatte. Ich hatte zuvor 5 Tage nach der Operation. noch keine bm?
Computer verbesserte Hysterektomie, sacrocopoplexy, vaginale Mesh-Netz, a & p Reparatur. Ich habe genommen Zäpfchen, Mutter und Magnesiumcitrat (dr Befehle) und immer noch nichts passiert, nicht einmal viel Gas. Ich habe so viel wie möglich spazieren
Ich habe lebhafte Träume jede Nacht. Soll ich die Propranolol stoppen?
Ich nehme Propranolol für Kopfschmerzen. Meine Kopfschmerzen verringert haben, aber ich habe lebhafte Träume meisten jede Nacht. Ich rede, bewegen und bin in enormen Stress. Ich habe mit meinem Arzt gesprochen, aber wir haben zu keinem Ergebnis gekom
Kinesiologie-Tape in Physiotherapie
Wenn Sie eine Verletzung oder Krankheit erlitten haben, die ein Problem mit Ihrem funktionellen oder die Mobilität der normalen Aktivität verursacht, können Sie aus dem Hand Dienste eines Physiotherapeuten profitieren Sie zu Ihrer vorherigen Maß an M
Hat sonst noch jemand Augenschmerzen und verschwommenes Sehen während Tribenzor hatte nehmen und sollte ich auch weiterhin zu übernehmen
Ich habe für 6 Monate auf Tribenzor gewesen und meine Vision in meinem rechten Auge ist wirklich verschwommen und manchmal das Auge selbst hat einen dumpfen Schmerz. Hat jemand anderes Vision Probleme gehabt? ----schneiden---- In Antwort auf kathyhan
Hohes Risiko von Blutgerinnseln Auch 12 Wochen nach der Schwangerschaft
Credit: Schwangerschaft Foto über Shutterstock Schwangere Frauen haben ein erhöhtes Risiko für Blutgerinnsel zu entwickeln, und jetzt eine neue Studie zeigt dieses Risiko für mindestens 12 Wochen erhöht bleibt, nachdem ein Baby zu liefern - doppelt s
Winterwandern Sicherheits-Tipps für Senioren
Walking ist eine der besten Möglichkeiten, regelmäßige Bewegung zu erhalten, wie Sie wenig Vorbereitung oder Ausrüstung erforderlich, und minimale Auswirkungen auf die Gelenke altern, mit. Wenn der Bürgersteig oder Spur mit gepackten Schnee oder Eis
Boston Scientific erhält FDA-Zulassung und CE-Kennzeichnung für Embolisation Katheter
Direxion verdrehbaren Microcather | Von Boston Scientific Boston Scientific (BSX) erhielt die FDA - Zulassung und der CE - Kennzeichnung für das Direxion verdrehbaren Microcatheter. Der Katheter ist die neueste Ergänzung des Unternehmens zu seiner pe
Menschen, die geboren Deaf Have-Superanblick Durch Veränderungen im Gehirn
Bildnachweis: Vladimir Mucibabic | Traumzeit Menschen, die oft taub sind, haben bessere Vision für ihren Mangel an Gehör zu bilden und neue Forschung hat ergeben, dass dieses Phänomen auf Veränderungen der Gehirnfunktion zugeschrieben werden. In eine